# Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477)

> **NCT02459119** · PHASE2 · COMPLETED · sponsor: **University of Alabama at Birmingham** · enrollment: 17 (actual)

## Conditions studied

- Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer)

## Interventions

- **DRUG:** Regorafenib

## Key facts

- **NCT ID:** NCT02459119
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05
- **Primary completion:** 2019-02
- **Final completion:** 2020-04
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2020-08-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02459119

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02459119, "Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02459119. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*